Industry Trials Stopped for Business or Funding Reasons (% of Stops)

## What this measures

Of the company-led interventional trials terminated over the last 12 months, the share whose stated reason cites a business, strategic, portfolio, commercial or funding decision (including discontinuing a development programme), in percent.

## Why it matters

This is the clearest read on pharma budgets and biotech cash: when funding tightens or companies reshuffle their pipelines, more trials are stopped for business reasons, not because the drug failed.

## How to read it

Higher means a larger part of early stops cite this reason. A stop can cite several reasons and count in more than one share; stops that give no reason, or only "sponsor decision", count in none.

## What it does not say

A registration is a plan, not a result: some registered trials never start, and size, cost and odds of success differ widely. Being listed does not mean a study was reviewed by the U.S. government.

## How it's built

Sponsors give a short free-text reason when they mark a trial terminated ("why stopped"). Palanor labels each reason with fixed word rules, published in its code (src/lib/clinicaltrials/reasons.ts), not a model. Phrases that deny a reason are removed first, because sponsors often add "not related to safety or efficacy" to business stops. The share is labelled stops divided by all terminated trials. Company-led interventional trials that ended with an actual completion date, counted in the month they ended and summed over the 12 months to the month shown (so each point is a 12-month window). Trials report their ending late, so the newest three complete months are not published, and the latest points can still move a little as reports arrive. Records are read from the API each week. History from January 2010.

## Source

ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly by /api/cron/clinicaltrials-pipeline-sync. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.